Repligen (RGEN)

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

Osakkeen Repligen Corporation Common Stock (RGEN) pre-market hinta tänään on 124,83 $ eli muutosta on ollut +0,06 % pre-market siitä, kun markkina viimeksi sulkeutui. Yrityksen markkina-arvo on 7,03 mrd. $, ja päivittäisen kaupankäynnin määrä on 18,00 $ osaketta. Edellinen sulkemishinta oli 124,75 $.

Aloitetaanko? Seuraa alla olevia vaiheita tai lue oppaamme siitä, miten ostaa Repligen osakkeita Krakenista alkaen 10 dollarista.